Abstract:
Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-glycans on VEGFR2 links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in response to VEGF blockade.
Registro:
Documento: |
Artículo
|
Título: | Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference |
Autor: | Croci, D.O.; Rabinovich, G.A. |
Filiación: | Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina Laboratorio de Glicómica, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
|
Palabras clave: | Angiogenesis; anti-VEGF; Cancer immunotherapy; Galectin; Glycans; Glycosylation; Inflammation; glycan; glycosyltransferase; immunoglobulin G3; immunoglobulin G4; vasculotropin receptor 2; article; carcinogenesis; catalysis; cell adhesion; glycosylation; human; hypoxia; lymphocyte proliferation; melanoma; nonhuman; protein binding; protein domain; protein processing; protein protein interaction; protein structure; sialylation; signal transduction; tumor microenvironment; tumor vascularization; upregulation |
Año: | 2014
|
Volumen: | 3
|
Número: | 6
|
DOI: |
http://dx.doi.org/10.4161/onci.29380 |
Título revista: | OncoImmunology
|
Título revista abreviado: | OncoImmunology
|
ISSN: | 21624011
|
CAS: | glycosyltransferase, 9033-07-2
|
Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_21624011_v3_n6_p_Croci |
Referencias:
- Folkman, J., Tumor angiogenesis: therapeutic implications (1971) N Engl J Med, 285, pp. 1182-1186. , http://dx.doi.org/10.1056/NEJM197111182852108, PMID:4938153
- Kowanetz, M., Ferrara, N., Vascular endothelial growth factor signaling pathways: therapeutic perspective (2006) Clin Cancer Res, 12, pp. 5018-5022. , http://dx.doi.org/10.1158/1078-0432.CCR-06-1520, PMID:16951216
- Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis (2011) Nature, 473, pp. 298-307. , http://dx.doi.org/10.1038/nature10144, PMID:21593862
- Bergers, G., Hanahan, D., Modes of resistance to antiangiogenic therapy (2008) Nat Rev Cancer, 8, pp. 592-603. , http://dx.doi.org/10.1038/nrc2442, PMID:18650835
- Chung, A.S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.M., Peale, F.V., An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy (2013) Nat Med, 19, pp. 1114-1123. , http://dx.doi.org/10.1038/nm.3291, PMID:23913124
- Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer (2012) Immunity, 36, pp. 322-335. , http://dx.doi.org/10.1016/j.immuni.2012.03.004, PMID:22444630
- Dennis, J.W., Nabi, I.R., Demetriou, M., Metabolism, cell surface organization, and disease (2009) Cell, 139, pp. 1229-1241. , http://dx.doi.org/10.1016/j.cell.2009.12.008, PMID:20064370
- Thijssen, V.L., Rabinovich, G.A., Griffioen, A.W., Vascular galectins: regulators of tumor progression and targets for cancer therapy (2013) Cytokine Growth Factor Rev, 24, pp. 547-558. , http://dx.doi.org/10.1016/j.cytogfr.2013.07.003, PMID:23942184
- Croci, D.O., Salatino, M., Rubinstein, N., Cerliani, J.P., Cavallin, L.E., Leung, H.J., Ouyang, J., Domaica, C.I., Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma (2012) J Exp Med, 209, pp. 1985-2000. , http://dx.doi.org/10.1084/jem.20111665, PMID:23027923
- Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Méndez-Huergo, S.P., Mascanfroni, I.D., Dergan-Dylon, S., Toscano, M.A., Ouyang, J., Glycosylation-dependent lectinreceptor interactions preserve angiogenesis in anti-VEGF refractory tumors (2014) Cell, 156, pp. 744-758. , http://dx.doi.org/10.1016/j.cell.2014.01.043, PMID:24529377
Citas:
---------- APA ----------
Croci, D.O. & Rabinovich, G.A.
(2014)
. Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference. OncoImmunology, 3(6).
http://dx.doi.org/10.4161/onci.29380---------- CHICAGO ----------
Croci, D.O., Rabinovich, G.A.
"Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference"
. OncoImmunology 3, no. 6
(2014).
http://dx.doi.org/10.4161/onci.29380---------- MLA ----------
Croci, D.O., Rabinovich, G.A.
"Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference"
. OncoImmunology, vol. 3, no. 6, 2014.
http://dx.doi.org/10.4161/onci.29380---------- VANCOUVER ----------
Croci, D.O., Rabinovich, G.A. Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference. OncoImmunology. 2014;3(6).
http://dx.doi.org/10.4161/onci.29380